When our beloved pets are diagnosed with cancer, it can be an emotionally and financially challenging time. As veterinary oncology advances, new and innovative cancer treatments are becoming available for our furry family members. However, these cutting-edge therapies can come with a significant price tag.
Nasal adenocarcinomas are relatively uncommon but represent nearly two-thirds of nasal tumors in dogs, which are locally invasive and have a higher risk of metastasis in later stages. Radiation therapy is the primary treatment to slow tumor growth, with patients living around one year on average. Newer approaches like metronomic chemotherapy and precision medicines targeting mutations show promise in delaying progression and metastasis.
Pulmonary adenocarcinoma is a common and aggressive form of lung cancer in dogs, accounting for nearly 80% of canine lung neoplasia cases. The primary treatment is surgical tumor removal, sometimes combined with chemotherapy or radiation therapy for inoperable cases. Prognosis depends on tumor size and grade, ranging from over 16 months for small, low-grade tumors to only 3 months for high-grade, metastatic cancers despite treatment.
Happy National Dog Day from all of us at FidoCure! Today, we celebrate the joy, companionship, and unconditional love that dogs bring into our lives. At FidoCure, our mission is to ensure that these beloved companions live longer, happier, and healthier lives, even when faced with the challenge of cancer.
Mast cell tumors are the most common skin tumors in dogs, developing from abnormal growth of mast cells, which are normally involved in allergic and immune responses. Treatment depends on tumor grade, size, and spread, ranging from surgery to radiation therapy to systemic therapies like chemotherapy and/or targeted therapy. Low-grade tumors that are completely removed with surgery carry the best prognosis while high-grade or metastatic tumors often require therapy beyond surgery and carry a more guarded prognosis. As always, consulting a veterinarian or veterinary oncologist is recommended for staging and personalized treatment planning.
FidoCure CEO Christina Lopes will present at the 2024 Animal Health Summit in Kansas City on August 26-27. The summit will showcase emerging companies and foster connections between innovators, investors, and industry leaders in animal health, nutrition, and technology. Attendees can also expect 1:1 business partnering opportunities, interactive experiences, and presentations from some of the world's leading minds in the field.
FidoCure to Transform the Precision Medicine Landscape with New Patent, Accelerating Drug Development for Dogs with Cancer
Squamous cell carcinoma (SCC) is the second most common oral tumor in dogs, arising from the lining of the gums and mouth. Treatment typically involves a multimodal approach, combining local therapies like surgery and radiation with systemic chemotherapy. However, traditional chemotherapy has limited efficacy, especially for tumors with higher metastatic potential like those in the tonsils or back of the mouth. As a result, targeted oral therapies like Palladia, are increasingly being used to improve outcomes.
FidoCure is pioneering a revolutionary approach to treating canine cancer - bringing the power of precision medicine from human oncology to veterinary care. As the first and only service of its kind, FidoCure provides genomic testing to identify the unique genetic markers driving each dog's cancer. This information can guide individualized treatment plans and leverage cutting-edge targeted therapies and innovative medicines precisely matched to a patient's disease profile. Genomic sequencing can also provide valuable insights into diagnosis and prognosis, offering a more comprehensive understanding of the patient's condition.
